Prophylactic effectiveness of suplatast tosilate in children with asthma symptoms in the autumn: a pilot study

• Published in: Allergology international 2014-06, Vol.63 (2), p.199-203
• Main Authors: Yoshihara, Shigemi, Yamada, Yumi, Fukuda, Hironobu, Tsuchiya, Takayoshi, Ono, Mika, Fukuda, Norimasa, Kanno, Noriko, Arisaka, Osamu
• Format: Article
• Language: English
• Subjects: Adolescent; Anti-Allergic Agents - administration & dosage; Anti-Allergic Agents - therapeutic use; Arylsulfonates - administration & dosage; Arylsulfonates - therapeutic use; asthma; Asthma - diagnosis; Asthma - drug therapy; Chemoprevention; Child; Child, Preschool; Disease Progression; Female; Humans; Male; pediatrics; Pilot Projects; seasonal; Seasons; Sulfonium Compounds - administration & dosage; Sulfonium Compounds - therapeutic use; suplatast tosilate; Th2 cytokines; Treatment Outcome
• ISSN: 1323-8930; 1440-1592
• DOI: 10.2332/allergolint.13-oa-0583

Exacerbations of bronchial asthma usually occur in the autumn. To our knowledge, however, the effectiveness of drugs for preventing exacerbations of asthma in the autumn has not been studied previously, except for leukotriene receptor antagonists and Omalizmab. This study compared the prophylactic effectiveness of suplatast tosilate with that of mequitazine in children with asthma symptoms, which is usually exacerbated in the autumn. The study group comprised 27 children aged 2 to 15 years who required treatment for asthmatic attacks during the past year and tested positive at least for mite allergen in the preceding autumn. The subjects were randomly assigned to receive either suplatast or mequitazine. The primary endpoint of this study was the number of days without symptoms during the 8 weeks of treatment. In addition, the Japanese Pediatric Asthma Control Program (JPAC) scores were also recorded every 2 weeks in each group. Overall, 14 patients received suplatast, and 13 received mequitazine for 8 weeks from September through early October. During follow-up, the number of days without symptoms and the total JPAC scores did not differ significantly between the groups. However, as compared with weeks 1 to 2 of treatment, the mean number of days without symptoms during weeks 7 to 8 increased significantly in only the suplatast group (8.6 vs. 11.5 days; p = 0.004). Our results suggest that short-term additional treatment with suplatast is useful for preventing asthma symptoms in children with asthma, which is usually exacerbated in the autumn.